The entire biotech sector has been in a bit of a funk for a while now. For proof of that just check how IBB ishares Nasdaq Biotechnology ETF has performed over the past year. Back in July of 2015 IBB got up close to $400....today its at les than $260, that's a drop of around 35%. RVX by contrast was trading around $2 last July, and now its sitting around $1.25 for a drop of around 37%.

Of note is that IBB is an ETF that includes companies like Pfizer, Teva, GSK etc....big profitable companies, so its a bit of an apple and oranges comparison. But IBB is a apple that is filled with profitable dividend paying companies, while RVX is a speculative orange....so the orange should perhaps be doing much much worse, and yet it hasn't dropped much more than the IBB ETF.

What's DM to do? He can't wave a magic wand and all of a sudden make revenues and profits appear. And sure we're getting some good press and peer reviewed articles out now....but its happening at a time when the entire sector is depressed.

And what if our new IR guy succeeds in bringing in attracting investors to RVX? What's to stop some other parties from going short 100 or 200 thousand and whacking any price gains right back down again?

I'm getting the sense that this down period for biotech is coming to an end....I'm starting to see a lot of spec bio companies make + moves, and its the small cap space that usually moves first in my experience. Once the entire sector starts moving I suspect RVX will have its day....and if it does everyone will be hailing DM as a genius.